It is likely that the heavy presence of most major drug companies in the U.S., with not only Pfizer and Amgen butalso foreign companies like Novartis searching to have much of their research presence in America, produce more science.
But corporate managers are also to blame for searching high and low to find actuaries who would supply such inaccurate forecasts in order to lower pension costs and improve profits.